TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female and male patients aged 12 to 21 years, inclusive, at the time of Visit 1~* Weight of ≥40 kg~* Documented history of current treatment with Inhaled corticosteroids (ICS) and long-acting β2 agonists (LABA)~* Morning pre-bronchodilator forced expiratory volume in 1 second (FEV1) of \>50% predicted at Visit 1 or Visit 2.~* Airway reversibility (FEV1 \>12% and 200 ml) demonstrated at Visit 1 or Visit 2 using the Maximum Post-bronchodilator Procedure OR~* Airway reversibility documented in the previous 12 months prior to Visit 1~* An exacerbation, 1 or more, that required oral corticosteroids in the previous year OR~* Any condition assessed by patient recall over the previous 2-4 weeks~Exclusion Criteria:~* Clinically important pulmonary disease other than asthma~* Known history of allergy or reaction to the Investigational Product formulation or influenza vaccine~* Receipt of an influenza vaccine within 90 days prior to randomization~* Poorly controlled asthma during the screening period that requires treatment with oral corticosteroids or a hospitalization/emergency room visit for the treatment of asthma~* Acute illness or evidence of significant active infection or known influenza infection during the current flu season

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Benralizumab (Type: EXPERIMENTAL): 1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
- Placebo (Type: PLACEBO_COMPARATOR): 1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients at least 18 years of age with moderate to severe active RA for at least 6 months;~* inadequate response to a stable dose of MTX;~* patients of reproductive potential must be using reliable methods of contraception.~Exclusion Criteria:~* major surgery (including joint surgery) within 8 weeks before entering study, or planned surgery within 6 months after entering study;~* prior treatment failure with an anti-tumor necrosis factor agent;~* women who are pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Nucleoside and nucleotide-naive subjects with chronic HBV infection~* Hepatitis B Surface antigen(HBsAg)-positive ≥6 months~* Detectable HBsAg~* HBV DNA ≥ 105 copies/mL by PCR~* ALT 1.3 to 10 x the ULN~* HBeAg negative, anti-hepatitis B Virus E antigen antibody (anti-HBeAb) positive status

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Entecavir + Lamivudine placebo (0-96 weeks)~Entecavir (96-240 weeks)
- Arm B (Type: ACTIVE_COMPARATOR): Lamivudine + Entecavir placebo (0-96 weeks)~Lamivudine (96-240 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of the Electronic Acupuncture Shoes: A Clinical Trial for Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~A. Diagnosed with chronic low back pain (pain that persists for more than 12 weeks ).~B. Subjects who agreed to be involved and signed the agreement, after being explained to by the investigators.~Exclusion Criteria:~A. Diagnosed with cancer . B. Early menopause ( before age 50 ) . C. Ovariectomized D. Under steroid therapy E. Rheumatoid arthritis F. With fractures or have undergone back surgery. G. Compression syndrome: e.g. HIVD ( Herniated Intervertebral Disc) , spinal disorder .~H. Renal calculus. I. Pacemaker users . J. Pregnant women or women who expect to be pregnant. K. Visual impairment . L. Diabetes. M. Visceral infections, e.g. pancreatitis, nephritis . N. Under other clinical trials (under medication or given other treatment) within 30 days before . O. Contraindications of ibuprofen. P. Poor function of heart, liver, GI tract or kidney. Q. Be suspected by the doctors of potential illness, disease or any other reason, which may endanger the subjects .

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Electronic Acupuncture Shoe (Type: EXPERIMENTAL): Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoe three times a week. 6 weeks of treatment was given. Subjects took placebo only in the first week. No placebo or medicine was prescribed to the subjects since the second week.
- Control group (Type: PLACEBO_COMPARATOR): Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy. Subjects took ibuprofen(400mg, TID) only in the first week. No placebo or medicine was prescribed to the subjects since the second week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of acute myeloid leukemia (AML) or blastic phase chronic myelogenous leukemia (CML)~  * Refractory AML defined as any of the following:~    * Failure to achieve complete response (CR) after 2 courses of induction chemotherapy~   * Persistent bone marrow blasts \> 40% after 1 course of induction chemotherapy~   * Relapse of disease within 3 months since CR~ * Relapsed AML defined as the following:~    * Any evidence of disease recurrence after CR (early relapse occurs within 3-12 months and late relapse occurs \> 12 months later)~ * No acute promyelocytic leukemia (AML-M3 FAB subgroup)~PATIENT CHARACTERISTICS:~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Bilirubin ≤ 2.0 mg/dL~* AST ≤ 2.5 times upper limit of normal~* No known chronic liver disease (e.g., chronic active hepatitis or cirrhosis)~Renal~* Creatinine \< 2.5 mg/dL (if 2.0-2.5 mg/dL, glomerular filtration rate must be measured and dose of cytarabine adjusted if necessary)~Cardiovascular~* No New York Heart Association grade III-IV heart disease~* No congestive heart failure~* No myocardial infarction within the past 6 months~* Ejection fraction ≥ 30%~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment~* No uncontrolled systemic active infection~* No known HIV infection~* No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drugs~* No history of other curatively treated malignancy except nonmelanoma skin cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No other concurrent biologic agents~Chemotherapy~* See Disease Characteristics~* No other concurrent chemotherapy~Endocrine therapy~* No concurrent birth control pills~Other~* More than 1 week since any prior investigational agent~* No other concurrent investigational agents or therapies~* No other concurrent anticancer agents~* No concurrent therapeutic anticoagulation with warfarin~  * Low molecular weight heparin or heparin allowed for therapeutic anticoagulation~ * Mini-dose warfarin (e.g., 1 mg per day) allowed for prophylaxis of central venous catheter thrombosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven metastatic carcinoma with the following light microscopic histologies: adenocarcinoma, poorly differentiated carcinoma(must have immunoperoxidase stains to rule out lymphoma, neuroendocrine carcinoma),or poorly differentiated squamous carcinoma.~* ECOG performance status 0-1~* No previous treatment with any systemic therapy~* Adequate kidney, liver and bone marrow function~* Be able to understand the nature of the study and give written informed consent~Exclusion Criteria:~* The following specific syndromes:~* Neuroendocrine carcinoma~* Women with adenocarcinoma isolated to axillary lymph nodes~* Women with adenocarcinoma isolated to peritoneal involvement~* Carcinoma involving only one site with resectable tumors at that site~* Squamous carcinoma limited to cervical, supraclavicular, or inguinal lymph nodes~* Uncontrolled brain metastases and all patients with meningeal involvement~* Women pregnant or lactating~* Clinically significant cardiovascular disease~* History of myocardial infarction or stroke within 6 months~* Clinical history of hemoptysis or hematemesis~* Patients with PEG tubes or G-tubes~* Proteinuria~* History of bleeding diathesis or coagulopathy~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have. You can then decide if you wish to participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab/Paclitaxel/Carboplatin/Erlotinib (Type: EXPERIMENTAL): Bevacizumab 15mg/kg IV infusion,Day 1 Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1 Carboplatin AUC 6.0 IV Day 1 Erlotinib 150 mg by mouth daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Individuals aged 18-75 years~* Individuals who had at least one and no more than 6 histologically confirmed CRAs removed within 6 months before recruitment~* Individuals who are able to swallow pills~* Individuals who voluntarily sign the consent form after being fully informed and understanding the purpose and procedure of this study, characters of the disease, effect of medication, methods of related examinations, and potential risk/benefits of the study 4.2 Exclusion criteria~* Individuals whose adenoma was not completely removed during previous colonoscopy~* Individuals with a history of familial adenomatous polyposis (FAP) or hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome)~* Individuals who are taking regularly aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclo-oxygenase 2 (COX2) inhibitors, calcium or vitamin D~* Individuals with a history of subtotal/total gastrectomy or partial bowel resection~* Individuals who are intolerant to another colonoscopy examination~* Individuals who are hypersensitive or intolerant to the drugs~* Individuals with severe heart, liver or kidney disease, or any cancer history~* Individuals presenting severe constipation~* Pregnant women, women during breast-feeding period, or women with expect pregnancy~* Individuals with mental diseases who are not able to cooperate~* Individuals who are involved in designing, planning or performing this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Berberine hydrochloride (Type: EXPERIMENTAL): supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
- placebo (Type: PLACEBO_COMPARATOR): identical-appearing placebo supplements for 2-3 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Trial in Acute Promyelocytic Leukemia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Signed written informed consent according to IGH/EU/GCP and national local laws~* Newly diagnosed APL by cytomorphology, confirmed also by molecular analysis\*.~* Age ≤18 \< 71 years~* WHO performance status 0 -2 included~* WBC at diagnosis ≤ 10 x 109/L~* Serum total bilirubin ≤ 3.0 mg/dL (≤ 51µmol/L)~* Serum creatinine ≤ 3.0 mg/dL (≤ 260 µmol/L)~The confirmation of diagnosis at genetic level (microspeckled PML nuclear distribution by PGM3 monoclonal antibody and/or PML/RARa fusion by RT-PCR and/or demonstration of t(15;17) by karyotyping) will be mandatory for patient eligibility. However, in order to avoid delay in treatment initiation, patients can be randomised on the basis of morphologic diagnosis only and before the results of genetic tests are available.~Exclusion criteria~* Age \< 18 and ≥ 71~* WBC at diagnosis \> 10 x 109/L~* Other active malignancy at time of study entry~* Lack of diagnostic confirmation at genetic level~* Significant arrhythmias, EKG abnormalities (\*see below) or neuropathy~* Other cardiac contraindications for intensive chemotherapy (L-VEF \<50%)~* Uncontrolled, life-threatening infections~* Severe non-controlled pulmonary or cardiac disease~* Women who are either pregnant or breast feeding, or of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they meet one of the following definitions:~  * Amenorrhea;~ * post surgical bilateral oophorectomy with or without hysterectomy;~ * using a highly effective method of birth control (defined as those which result in a failure rate less than 1% per year) when used consistently and correctly such as implants, injectables, oral contraceptives, IUDs, sexual abstinence or vasectomized partner.~* Concomitant severe psychiatric disorder~* HIV positivity~  \*EKG abnormalities:~ * Congenital long QT syndrome;~ * History or presence of significant ventricular or atrial tachyarrhythmia~ * Clinically significant resting bradycardia (\<50 beats per minute)~ * QTc \> 450 msec on screening EKG (using the QTcF formula detailed on page 18)~ * Right bundle branch block plus left anterior hemiblock, bifascicular block~* Use of other investigational drugs at the time of enrolment or within 30 days before study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ARM A - ATO/ATRA (Type: EXPERIMENTAL): None
- ARM B - ATRA (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acne vulgaris~* Willing to avoid excessive or prolonged exposure to ultraviolet light (eg, sunlight, tanning beds) throughout the study~Exclusion Criteria:~* Severe cystic acne, acne conglobata, acne fulminans, or secondary acne~* Use of phototherapy devices (eg, ClearLight™), energy-based devices, adhesive cleansing strips (eg, Pond's®, Biore®), or cosmetic procedures (eg, facials, peeling, comedo extraction) in the past week~* Use of anti-inflammatory medications, salicylic acid; corticosteroids, antibiotics, antibacterials (including benzoyl peroxide-containing products \[eg, benzamycin\]), retinoids; other topical acne treatments (eg, photodynamic therapy, medicated soaps such as those containing benzoyl peroxide, salicylic acid, sulfur, or sodium sulfacetamide) in the past 2 weeks~* Use of birth control pills strictly for acne control

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dapsone Gel (Type: EXPERIMENTAL): Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
- Dapsone Gel Vehicle (Type: PLACEBO_COMPARATOR): Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Healthy subject of either gender,~2. Age 12 to 18 months ,~3. Consent form signed by both parent(s) or by the legal representative properly informed about the study,~4. Parent(s) / legal representative able to understand the protocol requirements and to fill in the Diary Card.~Exclusion Criteria:~1. Prior receipt of measles, mumps, rubella or varicella vaccine either alone or in combination vaccine,~2. Known or suspected clinical history of infection with measles, mumps, rubella, varicella or zoster,~3. Any recent (≤30 days) exposure to measles, mumps or rubella,~4. Any recent (≤30 days) exposure to varicella or zoster involving:~5. Any recent (≤3 days) history of febrile illness~6. Any severe chronic disease,~7. Active untreated tuberculosis,~8. Known personal history of seizures,~9. Any known blood dyscrasia, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems,~10. Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection,~11. Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed~12. Any recent tuberculin test (≤7 days) or scheduled tuberculin test through visit 2,~13. Any previous (≤150 days) receipt of immune serum globulin or any blood-derived products or scheduled to be administered through visit 2,~14. Any recent receipt of an inactivated or a live vaccine (≤30 days) or scheduled vaccination through visit 2

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Detrol LA In Men With Overactive Bladder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of OAB (frequency more than 8 per day and Urgency more than 1 episode per day confirmed by bladder diary)~Exclusion Criteria:~* Significant hepatic or renal disease, history of radiation treatment

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete